glp 1 questionnaire Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study Comparison of GLP-1-receptor agonists |
Description
the documented protocol is monotherapy
If approvals land on schedule, 2026 may see the first real-world showdown between biased and traditional analogsredefining metabolic endpoints and cost expectations for millions of patients
Tracking, Coaching & Companions Companion products have the potential to help GLP-1 patients stay on their prescriptions by removing the complexity of taking the drugs
Published: Version of record: DOI:
Even though extensive research has been conducted, depression remains incompletely understood owing to the scarcity of biomarkers and the heterogeneity of precipitating causes, such as chronic stress (Kessler et al., 2005
Other neurological symptoms such as peripheral neuropathy, paresthesias, or allodynia have not been consistently reported as adverse effects attributable to semaglutide in controlled trials
